Rezolute Inc (RZLT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rezolute Inc (RZLT) has a cash flow conversion efficiency ratio of -0.159x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.32 Million) by net assets ($128.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See RZLT equity financing ratio to measure how much of total assets are equity-financed.
Rezolute Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Rezolute Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how aggressively does Rezolute Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Rezolute Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rezolute Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Moury Construct SA
BR:MOUR
|
0.210x |
|
AIM Industrial Growth Freehold and Leasehold Real Estate Investment Trust
BK:AIMIRT
|
-0.073x |
|
Cogstate Ltd
AU:CGS
|
0.235x |
|
Top Bright Holding Co Ltd
TW:8499
|
0.028x |
|
Bear Creek Mining Corporation
V:BCM
|
0.192x |
|
T&L Co. Ltd
KQ:340570
|
0.049x |
|
China Lilang Limited
F:5LX
|
0.070x |
|
KNEAT.COM INC.
F:FOBK
|
-0.047x |
Annual Cash Flow Conversion Efficiency for Rezolute Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Rezolute Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Rezolute Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $162.13 Million | $-69.08 Million | -0.426x | +10.13% |
| 2024-06-30 | $121.00 Million | $-57.37 Million | -0.474x | -23.82% |
| 2023-06-30 | $116.17 Million | $-44.48 Million | -0.383x | -44.46% |
| 2022-06-30 | $149.47 Million | $-39.62 Million | -0.265x | +66.16% |
| 2021-06-30 | $26.10 Million | $-20.44 Million | -0.783x | +76.13% |
| 2020-06-30 | $7.37 Million | $-24.17 Million | -3.281x | +62.43% |
| 2019-06-30 | $1.75 Million | $-15.30 Million | -8.735x | -345.15% |
| 2018-06-30 | $-3.96 Million | $-14.11 Million | 3.563x | +328.28% |
| 2017-06-30 | $8.53 Million | $-13.31 Million | -1.561x | -30.56% |
| 2016-06-30 | $8.77 Million | $-10.49 Million | -1.196x | -52.91% |
| 2015-06-30 | $9.05 Million | $-7.08 Million | -0.782x | -58.15% |
| 2014-06-30 | $6.41 Million | $-3.17 Million | -0.494x | -226.40% |
| 2013-06-30 | $-4.16 Million | $-1.63 Million | 0.391x | +1147.91% |
| 2012-06-30 | $-1.29 Million | $-40.40K | 0.031x | -- |
About Rezolute Inc
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for th… Read more